Virotherapy | Jotup

Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to Present at Oncolytic Virotherapy Summit 2023 on December 13

Retrieved on:

Monday, December 11, 2023

Seneca Therapeutics, Inc. (STI), announced today that Dr. Paul Hallenbeck will present a talk at the 8th Oncolytic Virotherapy Summit 2023 entitled “Assessing the Benefits and Challenges of Intravenous Delivery of Oncolytic Viruses”.

Key Points:

Seneca Therapeutics, Inc. (STI), announced today that Dr. Paul Hallenbeck will present a talk at the 8th Oncolytic Virotherapy Summit 2023 entitled “Assessing the Benefits and Challenges of Intravenous Delivery of Oncolytic Viruses”.
In his talk, Dr. Hallenbeck will discuss the challenges inherent in doing multiple (IV) intravenous administrations of oncolytic viruses, where the field is meeting these challenges, and present data on the development of multiple IV technology for STI’s oncolytic virus SVV-001, a clinical stage oncology product.
“There are several important hurdles to be overcome to develop the capability of performing multiple intravenous delivery of an oncolytic virus,” said Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics.
“These include cost of goods, high cancer target selectivity, elimination and/or avoidance of existing neutralizing antibodies and obtaining significant replication at the tumor site.

KaliVir Immunotherapeutics Appoints Viral Immunotherapy Researcher Grant McFadden, Ph.D., to its Board of Directors

Retrieved on:

Wednesday, May 10, 2023

PITTSBURGH, May 10, 2023 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the appointment of Grant McFadden, Ph.D., to its Board of Directors.

Key Points:

PITTSBURGH, May 10, 2023 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the appointment of Grant McFadden, Ph.D., to its Board of Directors.
McFadden is the director of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy and a Professor at Arizona State University.
He was co-founder and Board member of OncoMyx Therapeutics and has served on advisory boards for numerous companies including Jennerex, DNAtrix and IMV.
"KaliVir has exciting technology and a stellar team and I am honored to join its Board of Directors as the company progresses its first candidate into the clinic," said McFadden.

Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences

Retrieved on:

Wednesday, August 4, 2021

Biotechnology, General Health, Pharmaceutical, Health, Cancer immunotherapy, Immunotherapy, Virotherapy

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2021 financial results on Tuesday, August 10, 2021 after the close of market.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2021 financial results on Tuesday, August 10, 2021 after the close of market.
Alpine will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day to discuss the results and provide a corporate update.
A live webcast of the presentation will be available online in the investor relations section of the companys website at https://ir.alpineimmunesciences.com/events .
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics.

Aditxt Provides Update on AditxtReprogramming’s™ Apoptotic DNA Immunotherapy Therapeutic Platform

Retrieved on:

Wednesday, August 4, 2021

Health, Diabetes, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Medicine, Immunology, Cancer immunotherapy, Immunotherapy, Virotherapy, Immune tolerance, Immune system, Psoriasis

Meanwhile, Aditxt has continued to strengthen the data set that will be supporting regulatory submissions for the Apoptotic DNA Immunotherapy (ADi) platform for evaluation of ADi in clinical studies for skin allografting and type 1 diabetes in addition to the trials planned for psoriasis.

Key Points:

Meanwhile, Aditxt has continued to strengthen the data set that will be supporting regulatory submissions for the Apoptotic DNA Immunotherapy (ADi) platform for evaluation of ADi in clinical studies for skin allografting and type 1 diabetes in addition to the trials planned for psoriasis.
Broadening the therapeutic programs to include MS is intended to address an important clinical need in addition to demonstrating the utility of ADi as an antigen-specific immune tolerance platform.
Aditxt is continuing to build its patent portfolio protecting ADi with the addition of new patent families in 2021.
Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming.

ReWalk Robotics Appoints Senior Biotech Executive, Jeannine Lynch, as Vice President of Strategy and Market Access

Retrieved on:

Monday, August 2, 2021

Assistive technology, BioMarin Pharmaceutical, Virotherapy, Life sciences, ReWalk, Articles, Health sciences

Ms. Lynch will focus on completing the building and implementation of ReWalks market access and reimbursement programs.

Key Points:

Ms. Lynch will focus on completing the building and implementation of ReWalks market access and reimbursement programs.
We are thrilled to add the skills and experience of Ms. Lynch to help our customers and build our business.
Prior to ReWalk, Ms. Lynch served as Senior Director of Patient Access Services at BioMarin Pharmaceuticals.
Im excited to join ReWalk, a team dedicated to driving innovation for patients who are dealing with spinal cord injury, stroke and other neurodegenerative disorders, said Jeannine Lynch, ReWalks incoming Vice President of Strategy and Market Access.

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Monday, August 2, 2021

Biotechnology, Pharmaceutical, Health, Oncology, Cancer immunotherapy, Immunotherapy, Virotherapy, Atara

These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of August 2, 2021, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points:

These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of August 2, 2021, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
Atara Biotherapeutics, Inc. ( @Atarabio ) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.
Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need.
Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021

Retrieved on:

Monday, August 2, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Virotherapy, IMV, Digital Picture Exchange, Immunotherapy

ET to discuss the companys second quarter 2021 financial and operational results.

Key Points:

ET to discuss the companys second quarter 2021 financial and operational results.
The webcast will be recorded and will then be available on the IMV website for 30 days following the call.
IMV is pioneering a novel class of cancer immunotherapies based on the Companys proprietary delivery platform (DPX).
IMV is also developing another DPX-based immunotherapy: DPX-SurMAGE, a dual targeted immunotherapy to be evaluated in subjects with bladder cancer.

Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021

Retrieved on:

Monday, August 2, 2021

Research, Stem cells, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Cancer immunotherapy, Immunotherapy, Virotherapy, Atara

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2021 financial results after market close on Monday, August 9, 2021.

Key Points:

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2021 financial results after market close on Monday, August 9, 2021.
Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Companys financial results and provide a corporate update.
Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID 13720150.
Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Oncorus Expands its Board with Appointment of Barbara Yanni

Retrieved on:

Thursday, July 29, 2021

Cancer immunotherapy, Immunotherapy, Virotherapy

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Barbara Yanni to fill a vacancy on its Board of Directors. Since her retirement from Merck & Co. in 2014, where she served as Vice President and Chief Licensing Officer, Ms. Yanni has served as a director of multiple publicly traded and privately held biopharmaceutical companies. She brings extensive experience in corporate development, licensing and financial evaluation to Oncorus, as the company advances its pipeline of intratumorally (iTu) administered oncolytic Herpes Simplex Virus immunotherapies and intravenously (IV) administered Synthetic viral RNA (vRNA) immunotherapies.

Key Points:

Later this year, we plan to report initial interim data from our ongoing Phase 1 study of ONCR-177 in patients.
Click here to read a white paper published by Oncorus leadership on the companys Synthetic vRNA Immunotherapy Platform and lead candidates.
Im thrilled to join Oncorus Board and work with Ted, the Oncorus team and my fellow Board members as we continue to chart an exciting future for Oncorus, focused exclusively on addressing persistent and serious unmet needs of cancer patients.
These documents are available under the SEC filings page of the Investors section of Oncorus website at http://investors.oncorus.com .

Pharmadrug Announces Positive Research Results of Cepharanthine to Treat Multiple Cancers

Retrieved on:

Wednesday, July 28, 2021

Cancer, Clusterin, Anti-inflammatory, Branches of biology, Virotherapy, Clusters of differentiation

Toronto, Ontario--(Newsfile Corp. - July 28, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the completion of their preclinical cancer study which evaluated cepharanthine-2HCl, the active pharmaceutical ingredient in PD-001, the Company's patented oral formulation of cepharanthine. The results from the study validate cepharanthine's potential in treating different types of cancer including esophageal, colorectal, liver and skin. The results also provide confidence in the Company's plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company.

Key Points:

Based on the de-risked and positive results from the study, the Company has initiated the following activities:
Broadening intellectual property strategy with planned filing of provisional patents on cepharanthine for specific cancers.
Cepharanthine has been shown in preclinical efficacy models to restore cancer cell sensitivity to multiple unrelated classes of chemotherapy.
In clinical research, Cepharanthine has been shown to exhibit multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties5.
The Company is focused on advancing the clinical development of an improved oral formulation of Cepharanthine (PD-001) to treat rare cancers and infectious diseases.